Louis Edward Tamayo, Chief Financial Officer of Lexeo Therapeutics, Inc., filed a Form 4 on November 18, 2026, disclosing the sale of 1,007 shares of common stock on November 17, 2026, to cover tax obligations arising from the release of restricted stock units.
Key Highlights
- Transaction date: 1,007 shares of Lexeo Therapeutics common stock were disposed of on November 17, 2026.
- Purpose: The filing states the sale "represents a sale to cover tax obligations on the release of restricted stock units."
- Weighted average price: Shares were sold at a weighted average price of $3.26, with individual trades ranging from $3.24 to $3.31.
- Remaining ownership: Following the transaction, Tamayo beneficially owned 91,900 shares directly.
- RSU component: The post-transaction total includes 75,603 restricted stock units.
- Reporting person role: Louis Edward Tamayo is identified as Chief Financial Officer of Lexeo Therapeutics, Inc.
CFO Tax-Coverage Sale Details for Lexeo Therapeutics
According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 18, 2026, Louis Edward Tamayo, Chief Financial Officer of Lexeo Therapeutics, Inc. (NASDAQ:LXEO), disposed of 1,007 shares of common stock on November 17, 2026. The filing identifies the transaction code as "S" and classifies the shares as disposed of (D). The stated reason is a sale to cover tax obligations triggered by the release of restricted stock units.
The transaction was executed across multiple trades. The filing notes that prices ranged from $3.24 to $3.31 per share, with $3.26 reported as the weighted average sale price. The filing further states that Tamayo "undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."
Following the reported transaction, Tamayo directly held 91,900 shares of Lexeo Therapeutics common stock, according to the filing. Of that total, 75,603 shares are identified as restricted stock units. The Form 4 was signed by Youjin Choi as Attorney-in-Fact on November 18, 2026, and indicates the filing was made by one reporting person.
What Was Disclosed
Lexeo Therapeutics CFO Louis Edward Tamayo disclosed a disposition of 1,007 common shares on November 17, 2026, at a weighted average price of $3.26, solely to cover taxes on RSU vesting, leaving him with 91,900 shares beneficially owned.



Please wait processing your request...